Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Preplanned interim results for the AVAST-M trial

No Thumbnail Available
Issue Date
2013
Our author(s)
Davidson, N.
Department
Keywords
Language
English
Publisher
American Society of Clinical Oncology
ISSN
0732-183X
eISSN
ISBN
Type
Conference paper
Citation
Corrie, P., Marshall, A., Goonewardena, M., Dunn, J. A., Middleton, M. R., Nathan, P. D., Gore, M. E., Davidson, N., Nicholson, S., Kelly, C. G., Marples, M., Danson, S., Marshall, E., Houston, S., Board, R. E., Waterston, A. M., Nobes, J., Harries, M., Barber, J. & Lorigan, P. 2013. Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Preplanned interim results for the AVAST-M trial. Journal of Clinical Oncology, 31, (18 SUPPL. 1).
DOI
Pubmed ID
Description